Efikasi dan Keamanan dari Pancreatic Enzyme Replacement Therapy pada Pasien Cystic Fibrosis : Sebuah Kajian Sistematis
نویسندگان
چکیده
ABSTRAK
 Sekitar 80-90% pasien cystic fibrosis akan mengalami pancreatic insuffiency. Keadaan ini menyebabkan terjadinya malabsorpsi lemak dan protein berpengaruh pada status nutrisi dari pasien. Terapi insufficiency adalah dengan pemberian enzyme replacement therapy (PERT) untuk meningkatkan absorpsi juga fibrosis. Tujuan kajian sistematis mengetahui efikasi keamanan terapi PERT yang sehingga dapat dijadikan acuan atau pedoman dalam PERT. Proses penelusuran pustaka melalui PUBMED Cohcrane Library menggunakan kata kunci Cystic Fibrosis Boolean operator “AND”. Penelitian terpilih sebanyak 14 kriteria berupa RCT, segala usia, insufficiency, membandingkan plasebo formulasi lain. Dari empat belas penelitian semua studi memperlihatkan peningkatan % CFA Peningkatan mencapai rentang > 60% sampai 80%. Studi sediaan menunjukan hasil bahwa mampu meningkatankan menjadi 70% sementara memiliki sekitar 40% dinilai relatif aman ditoleransi oleh fibrosis.
 ABSTRACT
 Approximately patients with will experience insufficiency. This condition cause the malabsorption of fats and proteins affect nutritional patients. Therapy is by administering to increase absorption fat in systematic review aimed determine efficacy safety administration who fibrosis, this can be used as reference or guideline The search strategy was undertaken using Cochrane Library, term were “PERT” “Cystic Fibrosis” wich combines use In total, studies include final criteria any age, compared placebo other formulations. All showed an from all reached a range Studies comparing that able while had about considered relatively safe well tolerated
منابع مشابه
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption.
OBJECTIVES Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore, the aim of the study was to assess the influence of both the PERT dose and the variability in th...
متن کاملSymptomatic increase in intracranial pressure following pancreatic enzyme replacement therapy for cystic fibrosis.
A newly diagnosed 5-month-old infant with cystic fibrosis (CF) developed signs and symptoms of increased intracranial pressure (ICP) within days of starting pancreatic enzyme replacement therapy. Symptoms promptly resolved on two occasions after stopping enzyme replacement. At 10 months of age, enzyme replacement was well tolerated.
متن کاملPancreatic Enzyme Replacement Therapy
Patients with chronic pancreatic insufficiency develop improper digestion due to the lack of digestive pancreatic enzymes. Such patients might complain of diarrhea and multi-nutrient deficiencies. Children with cystic fibrosis are at an increased risk of developing pancreatic insufficiency, while adults can develop chronic pancreatitis due to gallbladder disease or alcohol consumption. Regardle...
متن کاملPancreatic enzyme supplements in cystic fibrosis.
Approximately 95% of patients in Northern Europe are pancreatic insufficient due to an inadequacy of their own pancreatic enzyme secretions (Littlewood et al, 2006). These patients need to take pancreatic enzyme replacement therapy (PERT) in order to prevent the symptoms of fat malabsorption. These symptoms include frequent pale, oily and offensive stools, abdominal pain, poor growth and defici...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Jurnal Sains dan Kesehatan
سال: 2021
ISSN: ['2303-0267', '2407-6082']
DOI: https://doi.org/10.25026/jsk.v3i4.582